PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
REGULATED INFORMATION
GHENT, Belgium, 30 April 2014 - Ablynx [Euronext Brussels: ABLX], today
announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Abingworth Management Limited and
Abingworth LLP.
Abingworth Management Limited and Abingworth LLP notified that they have dropped
below the 10% threshold (from 10.01% to 9.99%) as a result of the warrant
exercise by some employees and consultants of the Company, which was announced
on 23 April 2014.
Full versions of all transparency notifications are available on the website of
Ablynx, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 30 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:Â Â +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
    +32 (0)473 39 50 68
e:Â edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t:Â Â +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:Â marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:Â Â +44 203 709 5700
e:Â ablynx@consilium-comms.com
pdf version of the press release:
http://hugin.info/137912/R/1781776/609730.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1781776]